Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK inks $1B-plus siRNA licensing pact with China-based Frontier Biotech for two early-stage kidney disease programs. The deal's structure — modest upfront,…
GSK backs siRNA modality through $1bn Frontier deal. The agreement gives GSK exclusive global rights outside China-origin development, with Frontier retaining…
Law firm advisory confirming GSK/Frontier exclusive worldwide siRNA license structure; describes agreement as prospective (will exclusively license), no close…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK entered a global exclusive licensing agreement with Shanghai Stock Exchange-listed Frontier Biotechnologies for two early-stage siRNA therapeutic candidates targeting inflammation-driven kidney diseases. GSK pays $40 million upfront with up to $963 million in development, regulatory, and commercial milestones, plus tiered royalties on global sales. Frontier advances the assets through Phase 1 in China and completes IND-enabling work; GSK assumes subsequent global clinical development, regulatory submissions, and commercialization. The deal extends GSK's siRNA pipeline following its earlier $745M Empirico COPD siRNA pact.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Frontier Biotechnologies Inc. (this deal) | 2026 | $1.0B | — |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2026 deals · GlaxoSmithKline plc deals · Immunology deals